Team
NanoRED is about people. We believe in people, and we recruit the best. Each of our core team members is a dedicated and successful scientist with a background in biotechnology and business. Each of our team members understands the science and biology that underpins our platform. We believe in both competence and passion. Our team shares the collective goal of bringing this powerful platform into the clinical realm to benefit patients. NanoRED's core team is supplemented by clinical oncologists, venture capitalists and successful biotechnology entrepreneurs who serve as trusted advisors.
Our History
|
In the fall of 2015, a group consisting of a graduate student and post-doctoral fellows at the Medical College of Wisconsin, the Blood Research Institute and the University of Wisconsin-Milwaukee saw an opportunity. A powerful new platform had the potential to deliver cancer therapeutics in an entirely new way to dramatically enhance tumor specificity. Gang Xin, PhD, Karthika Divakaran, PhD, and Johnathan Ebben, MD, PhD, came together to participate in the Nanotechnology Startup Challenge in Cancer, sponsored by the National Cancer Institute and the Center for Advancing Innovation. Together, they built a team and collected the expertise necessary to develop a credible, viable business plan to take precision-delivery using IR-triggered liposomes to the clinic and the patients that needed it most. Competing against teams from around the world, this group built a company that won the Nanotechnology Startup Challenge and impressed judges from the realms of venture capital and biotechnology with their ability to devise and execute a go-to-market strategy with the potential to transform cancer therapy. As NanoRED progresses, we are working to continue the process that began with our victory in the NSCSquared Challenge by moving from idea to reality--from preclinical validation to clinical trials to standard of care.
|